RARE

Ultragenyx Pharmaceutical Inc.

24.68

USD

RARE Earnings Reports

Positive Surprise Ratio

RARE beat 20 of 40 last estimates.

50%

Next Report

Next Week

Date of Next Report

Feb 12, 2026

Estimate for Q4 25 (Revenue/ EPS)

$199.79M

-$1.13

Implied change from Q3 25 (Revenue/ EPS)

+24.92%

-37.57%

Implied change from Q4 24 (Revenue/ EPS)

+21.18%

-18.71%

Ultragenyx Pharmaceutical Inc. earnings per share and revenue

On Nov 04, 2025, RARE reported earnings of -1.81 USD per share (EPS) for Q3 25, missing the estimate of -1.25 USD, resulting in a -43.74% surprise. Revenue reached 159.93 million, compared to an expected 170.04 million, with a -5.95% difference. The market reacted with a -1.82% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 22 analysts forecast an EPS of -1.13 USD, with revenue projected to reach 199.79 million USD, implying an decrease of -37.57% EPS, and increase of 24.92% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Immunovant, Inc. Common Stock

Report Date

Feb 06, 2026 For Q3 26

Estimate

-$0.72

Actual

-$0.61

Surprise

+16.27%

Adaptive Biotechnologies Corporation Common Stock

Report Date

Feb 05, 2026 For Q4 25

Estimate

-$0.18

Actual

-$0.09

Surprise

+51.33%

Amgen Inc

Report Date

Feb 03, 2026 For Q4 25

Estimate

$4.82

Actual

$5.29

Surprise

+9.56%

Bristol-Myers Squibb Co.

Report Date

Feb 05, 2026 For Q4 25

Estimate

$1.12

Actual

$1.26

Surprise

+11.88%

GSK plc - ADR

Report Date

Feb 04, 2026 For Q4 25

Estimate

$0.23

Actual

$0.49

Surprise

+111.36%

Biogen Inc. Common Stock

Report Date

Feb 06, 2026 For Q4 25

Estimate

$1.62

Actual

$1.99

Surprise

+22.39%

Illumina Inc

Report Date

Feb 05, 2026 For Q4 25

Estimate

$1.24

Actual

$1.35

Surprise

+8.01%

QIAGEN N.V.

Report Date

Feb 04, 2026 For Q4 25

Estimate

$0.64

Actual

$0.62

Surprise

-3.32%

Arrowhead Research Corporation

Report Date

Feb 05, 2026 For Q1 26

Estimate

$0.25

Actual

$0.22

Surprise

-14.76%

Bio-Techne Corp.

Report Date

Feb 04, 2026 For Q2 26

Estimate

$0.44

Actual

$0.46

Surprise

+3.95%

FAQ

What were Ultragenyx Pharmaceutical Inc.'s earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Ultragenyx Pharmaceutical Inc. reported EPS of -$1.81, missing estimates by -43.74%, and revenue of $159.93M, -5.95% below expectations.

How did the market react to Ultragenyx Pharmaceutical Inc.'s Q3 2025 earnings?

The stock price moved down -1.82%, changed from $32.46 before the earnings release to $31.87 the day after.

When is Ultragenyx Pharmaceutical Inc. expected to report next?

The next earning report is scheduled for Feb 12, 2026.

What are the forecasts for Ultragenyx Pharmaceutical Inc.'s next earnings report?

Based on 22 analysts, Ultragenyx Pharmaceutical Inc. is expected to report EPS of -$1.13 and revenue of $199.79M for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.